BioDelivera develops virus-like particles—nanostructures without genetic material—to target tissues for oncology, autoimmune, and central nervous system (CNS) treatments. The platform aims to improve precision in medicine delivery across multiple disease areas. The company focuses on engineering these particles for therapeutic applications.
Ikeda and Orikeda Trashi win first prize and $12,000 at UT Dallas’s Big Idea competition for **Biodelivera**, a platform using virus-like particles to deliver cancer therapy directly to tumors. The twins developed the solution as part of their submission in the student innovation showcase. Their technology targets precise tumor treatment, addressing a critical need in oncology.
Ikeda and Orikeda Trashi secured first place and **$12,000** in the University of Texas at Dallas (UTD) Big Idea Competition for **Biodelivera**, a platform designed to deliver cancer therapy directly to tumor sites. Their innovation targets precision treatment by improving drug delivery mechanisms. The competition highlights student-driven advancements in biomedical engineering.
BioDelivera and Vaucluse, two student-led teams developing chemotherapy innovations, win first place in the Big Idea Competition. The teams competed against over 100 applicants, securing cash prizes and networking opportunities. Their solutions focus on advancing chemotherapy delivery methods.
